PURPOSE: To report response rate, pelvic tumor control, survival, and late toxicity after treatment with combined radiotherapy and hyperthermia (RHT) for patients with locally advanced cervical carcinoma (LACC) and compare the results with other published series. METHODS AND MATERIALS: From 1996 to 2005, a total of 378 patients with LACC (International Federation of Gynecology and Obstetrics Stage IB2-IVA) were treated with RHT. External beam radiotherapy (RT) was applied to 46-50.4 Gy and combined with brachytherapy. The hyperthermia (HT) was prescribed once weekly. Primary end points were complete response (CR) and local control. Secondary end points were overall survival, disease-specific survival, and late toxicity. Patient, tumor, and treatment characteristics predictive for the end points were identified in univariate and multivariate analyses. RESULTS: Overall, a CR was achieved in 77% of patients. At 5 years, local control, disease-specific survival, and incidence of late toxicity Common Terminology Criteria for Adverse Events Grade 3 or higher were 53%, 47%, and 12%, respectively. In multivariate analysis, number of HT treatments emerged as a predictor of outcome in addition to commonly identified prognostic factors. CONCLUSIONS: The CR, local control, and survival rates are similar to previously observed results of RHT in the randomized Dutch Deep Hyperthermia Trial. Reported treatment results for currently applied combined treatment modalities (i.e., RT with chemotherapy and/or HT) do not permit definite conclusions about which combination is superior. The present results confirm previously shown beneficial effects from adding HT to RT and justify the application of RHT as first-line treatment in patients with LACC as an alternative to chemoradiation.
PURPOSE: To report response rate, pelvic tumor control, survival, and late toxicity after treatment with combined radiotherapy and hyperthermia (RHT) for patients with locally advanced cervical carcinoma (LACC) and compare the results with other published series. METHODS AND MATERIALS: From 1996 to 2005, a total of 378 patients with LACC (International Federation of Gynecology and Obstetrics Stage IB2-IVA) were treated with RHT. External beam radiotherapy (RT) was applied to 46-50.4 Gy and combined with brachytherapy. The hyperthermia (HT) was prescribed once weekly. Primary end points were complete response (CR) and local control. Secondary end points were overall survival, disease-specific survival, and late toxicity. Patient, tumor, and treatment characteristics predictive for the end points were identified in univariate and multivariate analyses. RESULTS: Overall, a CR was achieved in 77% of patients. At 5 years, local control, disease-specific survival, and incidence of late toxicity Common Terminology Criteria for Adverse Events Grade 3 or higher were 53%, 47%, and 12%, respectively. In multivariate analysis, number of HT treatments emerged as a predictor of outcome in addition to commonly identified prognostic factors. CONCLUSIONS: The CR, local control, and survival rates are similar to previously observed results of RHT in the randomized Dutch Deep Hyperthermia Trial. Reported treatment results for currently applied combined treatment modalities (i.e., RT with chemotherapy and/or HT) do not permit definite conclusions about which combination is superior. The present results confirm previously shown beneficial effects from adding HT to RT and justify the application of RHT as first-line treatment in patients with LACC as an alternative to chemoradiation.
Authors: Mario L Fabiilli; Rahul A Phanse; Alexander Moncion; J Brian Fowlkes; Renny T Franceschi Journal: Ultrasound Med Biol Date: 2015-12-19 Impact factor: 2.998
Authors: Rachel L Atkinson; Mei Zhang; Parmeswaran Diagaradjane; Sirisha Peddibhotla; Alejandro Contreras; Susan G Hilsenbeck; Wendy A Woodward; Sunil Krishnan; Jenny C Chang; Jeffrey M Rosen Journal: Sci Transl Med Date: 2010-10-27 Impact factor: 17.956
Authors: Margarethus M Paulides; Paul R Stauffer; Esra Neufeld; Paolo F Maccarini; Adamos Kyriakou; Richard A M Canters; Chris J Diederich; Jurriaan F Bakker; Gerard C Van Rhoon Journal: Int J Hyperthermia Date: 2013-05-14 Impact factor: 3.914
Authors: S Triantopoulou; E Efstathopoulos; K Platoni; N Uzunoglou; N Kelekis; V Kouloulias Journal: Clin Transl Oncol Date: 2012-11-21 Impact factor: 3.405
Authors: Arlene L Oei; Lianne E M Vriend; Johannes Crezee; Nicolaas A P Franken; Przemek M Krawczyk Journal: Radiat Oncol Date: 2015-08-07 Impact factor: 3.481